Does Ligand (LGND) Have the Potential to Rally 41.24% as Wall Street Analysts Expect?Zacks Investment Research • 04/20/23
Wall Street Analysts Predict a 53.67% Upside in Ligand (LGND): Here's What You Should KnowZacks Investment Research • 04/04/23
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%Zacks Investment Research • 03/17/23
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/23/23
Ligand's Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA NephropathyBusiness Wire • 02/17/23
Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical TrialPRNewsWire • 02/16/23
Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumBusiness Wire • 01/06/23
Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?Zacks Investment Research • 12/19/22